Redefining the Role of Pharmacy in Diabetes Treatment

Redefining the Role of Pharmacy in Diabetes Treatment

SGLT2 Inhibitors are Protective Against Type 2 Diabetes-Related Renal Events

SGLT2 Inhibitors are Protective Against Type 2 Diabetes-Related Renal Events

Sodium glucose cotransporter 2 (SGLT2) inhibitors not only are effective in lowering blood glucose levels and reducing cardiovascular risks in type 2 diabetes, but a new study asserts the drugs also could be helpful in lowering the risks of serious renal events...
How T2D Patients View Initiation, Persistence with Basal Insulin Therapy

How T2D Patients View Initiation, Persistence with Basal Insulin Therapy

Health care providers play a major role in whether type 2 diabetes patients initiating basal insulin persist with the therapy or discontinue it, a new survey suggests...
Insulin Pump Shows ‘Excellent’ Results in Real-World Usage

Insulin Pump Shows ‘Excellent’ Results in Real-World Usage

An insulin pump which has been on the market four several years now has proven effective in helping patients maintain their blood glucose level...
Affordable Insulin Option More Viable with Wearable Device

Affordable Insulin Option More Viable with Wearable Device

Patients with type 2 diabetes using a wearable delivery device can have better success using regular human insulin, while also taking less of a hit to their wallets...
Dulaglutide Approved for Reduction of Major Adverse Cardiovascular Events in Type 2 Diabetes Patients

Dulaglutide Approved for Reduction of Major Adverse Cardiovascular Events in Type 2 Diabetes Patients

The FDA has approved dulaglutide as the first type 2 diabetes medication to reduce major adverse cardiovascular events in adults with diabetes and established cardiovascular disease...

Loading...